Clinical trials: Stage III Pancreatic Cancer
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
This phase I trial tests the safety, side effects and best dose of TR-002 for the treatment of solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced)…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma
- Trial name
- NCT07189195
- Testing
- TR-002
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of California, Davis
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
Phase I trial to study the effectiveness of combining UCN-01 with gemcitabine in treating patients who have unresectable or metastatic pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00039403
- Testing
- 7-hydroxystaurosporine, gemcitabine hydrochloride, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Pancreas, Stage II Pancreatic Cancer
Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
Drugs used in chemotherapy, such as capecitabine and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Adenocarcinoma of the Pancreas, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00114179
- Testing
- capecitabine, radiation therapy, bevacizumab
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Fatigue, Nausea and Vomiting
Nurse-Provided Care or Standard Care in Treating Patients With Pancreatic Cancer
RATIONALE: Meeting with a nurse to assess symptoms and quality of life may be more effective than standard care in treating patients with pancreatic cancer.
- Conditions
- Fatigue, Nausea and Vomiting, Pain, Pancreatic Cancer
- Trial name
- NCT00902733
- Testing
- medical chart review, questionnaire administration, fatigue assessment and management
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- City of Hope Medical Center
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer
This phase I trial is studying the side effects and best dose of erlotinib when given together with gemcitabine and radiation therapy in treating patients with locally advanced unresectable pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00063947
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride, radiation therapy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumors, Advanced Cancer
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Assess whether therapy with axitinib, a potent angiogenic inhibitor of the tyrosine kinase receptors of VEGF bioavailable by oral administration, is capable of improving PFS in patients with advanced G1-G2 NETs of nonpancreatic…
- Trial name
- NCT01744249
- Testing
- Axitinib, Sandostatin LAR
- Where
- 26 sites in Germany, Italy and 2 more
- Volunteers
- 256 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Recurrent Colon Cancer, Recurrent Gastric Cancer
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating…
- Conditions
- Recurrent Colon Cancer, Recurrent Gastric Cancer, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer
- Trial name
- NCT01191684
- Testing
- laboratory biomarker analysis, enzyme-linked immunosorbent assay, flow cytometry
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer
High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
This randomized phase II trial studies how well high or standard intensity radiochemotherapy after gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) work compared with…
- Trial name
- NCT01921751
- Testing
- low intensity radiation therapy, Capecitabine, Gemcitabine
- Where
- 46 sites in United States
- Volunteers
- 20 people
- Sponsor
- Radiation Therapy Oncology Group
Pancreatic Cancer
Combination Chemotherapy Followed by Chemotherapy and Radiation Therapy and/or Surgery in Treating Patients Who Have Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with radiation therapy and/or surgery may kill more tumor cells.
- Trial name
- NCT00003332
- Testing
- cisplatin, gemcitabine hydrochloride, surgical procedure
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- NYU Langone Health
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Pancreatic Neoplasms
Randomized Trial of EUS Neurolysis in Pancreas Cancer
This is a clinical trial to determine more effective methods of controlling the pain in pancreatic cancer. Although narcotic pain medication are effective, they have many side effects and are underutilized due to social stigma…
- Trial name
- NCT00279292
- Testing
- Celiac Plexus Neurolysis
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
This phase Ib trial studies the side effects and best dose of Hsp90 inhibitor XL888 when given together with pembrolizumab in treating patients with advanced gastrointestinal cancer that has spread to other places in the body.
- Conditions
- Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Colorectal Carcinoma, Recurrent Pancreatic Carcinoma
- Trial name
- NCT03095781
- Testing
- XL888, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- Emory University
KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting
HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer
This study investigates the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation. Patients were randomized 1:1 to receive either the experimental regimen HRS-4642 plus AG or the control regimen AG alone.
- Trial name
- NCT07232875
- Testing
- HRS-4642 + AG
- Where
- China
- Volunteers
- 588 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Pancreatic Cancer
Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00335543
- Testing
- cisplatin, gemcitabine hydrochloride, adjuvant therapy
- Where
- 17 sites in Austria, Germany and 1 more
- Volunteers
- 254 people
- Sponsor
- Interdisziplinare Arbeitsgruppe Gastrointestinaler Tumore der Deutschen Krebsgesellschaft
Pancreatic Cancer, Thromboembolism
Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00462852
- Testing
- dalteparin, gemcitabine hydrochloride, diagnostic laboratory biomarker analysis
- Where
- 8 sites in United Kingdom
- Volunteers
- 120 people
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Breast Cancer, Colorectal Cancer
Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Conditions
- Breast Cancer, Colorectal Cancer, Pancreatic Cancer
- Trial name
- NCT00369109
- Testing
- biologic sample preservation procedure, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Pancreatic Cancer
Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as erlotinib use different ways to stimulate the immune system and stop cancer…
- Trial name
- NCT00026338
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- 173 sites in United States, Argentina and 17 more
- Volunteers
- 569 people
- Sponsor
- NCIC Clinical Trials Group
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
This phase II trial studies how well combination chemotherapy with or without oregovomab followed by stereotactic body radiation therapy (SBRT) and nelfinavir mesylate works in treating patients with pancreatic cancer that has…
- Conditions
- Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer
- Trial name
- NCT01959672
- Testing
- 4-Dimensional Computed Tomography, Fluorouracil, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Nebraska
Neuroendocrine Tumors
Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors
A randomized, double-blind, placebo controlled, multi-center Phase III study to assess the efficacy of Surufatinib 300 mg once a day in treating advanced pancreatic neuroendocrine tumors.
- Trial name
- NCT02589821
- Testing
- Surufatinib
- Where
- 5 sites in China
- Volunteers
- 195 people
- Sponsor
- Hutchison Medipharma Limited